Integration of denosumab therapy in the management of giant cell tumors of bone

被引：7
|
作者：
Miles, Daniel T. [1 ]
Voskuil, Ryan T. [2 ,3 ]
Dale, Wood [4 ]
Mayerson, Joel L. [2 ,3 ]
Scharschmidt, Thomas J. [2 ,3 ]
机构：
[1] Univ Tennessee, Coll Med, Dept Orthopaed Surg, Chattanooga, TN USA
[2] Ohio State Univ, James Canc Hosp, Div Musculoskeletal Oncol, Wexner Med Ctr,Nationwide Childrens Hosp, Columbus, OH 43210 USA
[3] Ohio State Univ, Solove Res Inst, Wexner Med Ctr, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[4] Univ Mississippi, Sch Med, Dept Orthopaed & Rehabil, University, MS 38677 USA
来源：
JOURNAL OF ORTHOPAEDICS | 2020年 / 22卷
关键词：
Denosumab; RANKL; Giant cell tumor of the bone (GCTB); PHASE-II TRIAL; LOCAL RECURRENCE; ZOLEDRONIC ACID; BREAST-CANCER; OPEN-LABEL; PROSTATE-CANCER; GENE-EXPRESSION; CATHEPSIN-K; RANK LIGAND; OSTEOPROTEGERIN;
D O I：
10.1016/j.jor.2020.03.020
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
引用
收藏
页码：38 / 47
页数：10
相关论文
共 50 条
  • [1] Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone
    Lipplaa, Astrid
    Dijkstra, Sander
    Gelderblom, Hans
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (04) : 329 - 335
  • [2] Giant cell tumour of bone in the denosumab era
    van der Heijden, Lizz
    Dijkstra, P. D. Sander
    Blay, Jean-Yves
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2017, 77 : 75 - 83
  • [3] Denosumab and giant cell tumour of bone-a review and future management considerations
    Xu, S. F.
    Adams, B.
    Yu, X. C.
    Xu, M.
    CURRENT ONCOLOGY, 2013, 20 (05) : E442 - E447
  • [4] Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone
    Traub, Frank
    Singh, Janith
    Dickson, Brendan C.
    Leung, Stephanie
    Mohankumar, Rakesh
    Blackstein, Martin E.
    Razak, Albiruni R.
    Griffin, Anthony M.
    Ferguson, Peter C.
    Wunder, Jay S.
    EUROPEAN JOURNAL OF CANCER, 2016, 59 : 1 - 12
  • [5] Giant Cell Tumors of the Bone: Changes in Image Features after Denosumab Administration
    Oguro, Sota
    Okuda, Shigeo
    Sugiura, Hiroaki
    Matsumoto, Shunsuke
    Sasaki, Aya
    Susa, Michiro
    Morioka, Hideo
    Jinzaki, Masahiro
    MAGNETIC RESONANCE IN MEDICAL SCIENCES, 2018, 17 (04) : 325 - 330
  • [6] Denosumab for the management of giant cell tumours of bone
    Papanikola, G.
    Aubry-Rozier, B.
    SWISS MEDICAL WEEKLY, 2017, 147 : 5S - 5S
  • [7] DENOSUMAB: A NEW TREATMENT OPTION FOR GIANT CELL TUMOR OF BONE
    Lewin, J.
    Thomas, D.
    DRUGS OF TODAY, 2013, 49 (11) : 693 - 700
  • [8] Denosumab for treating giant cell tumor of bone
    Jagiello-Wieczorek, Ewelina
    Pienkowski, Andrzej
    Rutkowski, Piotr
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (10): : 1219 - 1229
  • [9] Denosumab for the treatment of giant cell tumor of the bone
    Brodowicz, Thomas
    Hemetsberger, Margit
    Windhager, Reinhard
    FUTURE ONCOLOGY, 2015, 11 (13) : 1881 - 1894
  • [10] Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy
    Xiang, Feifan
    Liu, Huipan
    Deng, Jia
    Ma, Wenzhe
    Chen, Yue
    CANCERS, 2022, 14 (23)
12345